Belantamab Mafodotin Shows Survival Benefit in Relapsed Multiple Myeloma: DREAMM-7 Trial Results

Belantamab Mafodotin Shows Survival Benefit in Relapsed Multiple Myeloma: DREAMM-7 Trial Results

November 23, 2024 Catherine Williams - Chief Editor Health

Belantamab Mafodotin and Multiple Myeloma Treatment

Belantamab mafodotin (Blenrep) is a treatment for relapsed or refractory multiple myeloma (RRMM). In the DREAMM-7 trial, it showed significant improvement in overall survival when combined with bortezomib (Velcade) and dexamethasone. This result marks a positive step in treating patients who have previously undergone at least one line of therapy.

Background on Multiple Myeloma

Multiple myeloma is a serious blood cancer that affects the plasma cells in the bone marrow. Patients often experience cycles of remission followed by relapse. The median time to relapse after initial treatment is approximately 26.9 months. Despite advancements in therapy, the need for effective options for relapsed patients remains.

Clinical Studies

Belantamab mafodotin is an anti-BCMA antibody-drug conjugate. It received FDA approval in August 2020 based on the DREAMM-2 trial. However, it faced market withdrawal in November 2022 due to inadequate results in the DREAMM-3 trial. GSK, the drug’s manufacturer, remains committed to finding solutions for patients with this challenging disease.

The DREAMM-7 trial involved 494 patients. Participants received either the combination of belantamab mafodotin with bortezomib and dexamethasone (BVd) or a similar regimen with daratumumab (DVd). The study assessed various outcomes, including progression-free survival (PFS) and overall survival (OS).

Safety and Efficacy

In terms of safety, adverse events were common. In the BVd group, 95% of patients experienced grade 3 or higher adverse events, compared to 78% in the DVd group. Ocular issues were notably higher in the BVd group (79% vs. 29% for DVd). Despite these challenges, the data indicates that BVd may provide meaningful benefits for patients facing RRMM.

Conclusion

Belantamab mafodotin, in combination with bortezomib and dexamethasone, shows promise for improving outcomes in patients with RRMM. Ongoing trials will better establish its role in treatment and provide more options for managing this difficult disease.